TELA
TELA Bio, Inc. (NASDAQ)
Healthcare — Medical Devices
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Price History
Fundamentals
| Market Cap | $32.23M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.29 |
| EPS (TTM) | $-0.79 |
| Dividend Yield | - |
| Profit Margin | -49.30% |
| Revenue Growth | 2.90% |
| ROE | -616.62% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $2.25 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 28.3 |
| Beta | 1.31 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.20 |
| 52-Week Low | $0.50 |
| 50-Day Avg | $0.87 |
| 200-Day Avg | $1.02 |
| Avg Volume | 168.6K |
| Volume | 1.1K |
Performance Analysis
NEUTRALTELA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report